Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject.
1. A method of treating a hematologic disease in a subject in need thereof via allogeneic graft administration with reduced concomitant graft rejection, the method comprising administering to the subject a therapeutically effective graft comprising immature hematopoietic cells being non-syngeneic with the subject, and a dose of primary tolerogenic cells for reducing in a subject rejection of said graft, said tolerogenic cells being CD4+CD25+ cells and wherein said tolerogenic cells are allogeneic and MHC-mismatched with the subject and with said graft, and wherein said primary tolerogenic cells are from one donor, thereby treating the hematologic disease in the subject.
2. The method of claim 1 , further comprising administering at least one immunosuppressant drug to the subject.
3. The method of claim 1 , wherein said dose of said tolerogenic cells is selected from a range of about 1 million cells per kilogram body weight to about 400 million cells per kilogram body weight.
4. The method of claim 1 , wherein said administering of said tolerogenic cells is effected prior to and/or concomitantly with said administering of said graft.
5. The method of claim 1 , further comprising the step of conditioning the subject under sublethal, lethal or supralethal conditions prior to said administering of said graft to the subject and/or prior to said administering of said dose of tolerogenic cells to the subject.
6. The method of claim 1 , wherein said allogeneic graft is MHC-mismatched with the subject.
7. The method of claim 1 , wherein said graft is a bone marrow cell graft.
8. A method of reducing in a subject rejection of a graft comprising immature hematopoietic cells being allogeneic with the subject, the method comprising
(a) administering the graft to the subject; and
(b) administering to the subject a dose of primary tolerogenic cells, said tolerogenic cells being CD4+CD25+ cells and wherein said tolerogenic cells are allogeneic and MHC-mismatched with the subject and with the graft, and wherein said primary tolerogenic cells are from one cell donor, thereby reducing in the subject rejection of the graft.
9. The method of claim 8 , further comprising administering at least one immunosuppressant drug to the subject.
10. The method of claim 8 , wherein said dose of said tolerogenic cells is selected from a range of about 1 million cells per kilogram body weight to about 400 million cells per kilogram body weight.
11. The method of claim 8 , further comprising the step of conditioning the subject under sublethal, lethal or supralethal conditions prior to said administering of said dose of tolerogenic cells to the subject.
12. The method of claim 8 , wherein said allogeneic graft is MHC-mismatched with the subject.
13. The method of claim 8 , wherein the graft is a bone marrow cell graft.
14. The method of claim 8 , wherein said administering of said tolerogenic cells is effected prior to and/or concomitantly with said administering of the graft.